RxDoctor Payments Data

Muhammad Ahsan, MD

Nephrology · Southfield, MINPI 1396725305

Payments from drug & device makers

$1,218in general payments, 2019–2025

Across 41 payments — averaging $29.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$385
  • Amgen$178
  • Medtronic$100
  • AbbVie$75
  • Johnson & Johnson$69
  • Boehringer Ingelheim$68
  • plus $343 from 14 others

What the payments were for

  • Travel & lodging$29124%
  • Food & beverage$90774%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,218 in reported general payments places this provider in the 55th percentile of 325 nephrology providers in Michigan.

See all nephrology providers in Michigan

Medicare billing

Part B allowed, 2024
$291,920
Medicare patients
272
Services billed
1,722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol210$197,835
JardianceEmpagliflozin146$134,963
InvokanaCanagliflozin39$42,334
KerendiaFinerenone52$38,600
LokelmaSodium Zirconium Cyclosilicate25$24,792
Sevelamer Carbonate30$6,962
Losartan Potassium196$2,170
Chlorthalidone57$1,334
Paricalcitol11$1,259
Calcium Acetate15$850
Carvedilol97$762
Bumetanide21$748
Calcitriol24$722
Nifedipine ErNifedipine17$471
Spironolactone43$394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$30$222,626235 claims
Boehringer IngelheimJardiance$68$134,963146 claims
Johnson & JohnsonInvokana$69$42,33439 claims
BayerKerendia$48$38,60052 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 325 nephrology providers in Michigan.

Other nephrology in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →